DXCM

DexCom, Inc.
$74.96
+1.94 (+2.66%)
Mkt Cap 28.93B
Volume 3,834,486
52W Range 54.11-89.98
Sector Healthcare
Beta 1.45
EPS (TTM) 2.40
P/E Ratio 31.23
Revenue (TTM) 4.82B
Rev Growth (5Y) +19.3%
EPS Growth (5Y) +10.3%
AlphaVal · Fair Value
What we estimate one share is worth
$89.51
Fair Value moderate signal
16.3% below fair value
Modeled from cash flows & growth.
AlphaQuality · Grade
How strong & durable the business is
A-
Platform & Compounding FCF
86.7 / 100 composite
A platform business that compounds free cash flow — graded A–F vs. similar companies.

Company Description

Track Record

Showing latest 4 periods • Swipe for more
Metric 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
Revenue 4.66B 4.03B 3.62B 2.91B 2.45B 1.93B 1.48B 1.03B 718.50M 573.30M 402.00M 259.20M
Net Income 836.30M 576.20M 541.50M 341.20M 216.90M 493.60M 101.10M (127.10M) (50.20M) (65.60M) (57.60M) (22.40M)
EPS 2.14 1.46 1.44 0.88 0.56 1.31 0.28 -0.36 -0.15 -0.20 -0.18 -0.07
Free Cash Flow 1.08B 630.70M 511.90M 304.70M 53.30M 276.60M 134.50M 56.10M 26.00M 500,000 15.70M 7.40M
FCF / Share 2.76 1.56 1.33 0.78 0.14 0.73 0.37 0.16 0.08 0.00 0.05 0.02
Operating CF 1.44B 989.50M 748.50M 669.50M 442.50M 475.60M 314.50M 123.20M 92.00M 56.20M 49.00M 23.60M
Total Assets 6.34B 6.48B 6.26B 5.39B 4.93B 4.29B 2.40B 1.92B 904.10M 402.80M 292.00M 184.60M
Total Debt 1.39B 2.59B 2.59B 2.15B 2.16B 1.84B 1.16B 1.02B 334.30M 6.70M 2.30M 4.60M
Cash & Equiv 917.70M 606.10M 566.30M 642.30M 1.05B 817.60M 446.20M 1.14B 441.50M 94.50M 86.10M 71.80M
Book Value 2.75B 2.10B 2.07B 2.13B 2.04B 1.83B 882.60M 663.30M 419.40M 283.80M 221.20M 140.20M
Return on Equity 0.30 0.27 0.26 0.16 0.11 0.27 0.11 -0.19 -0.12 -0.23 -0.26 -0.16
DXCM News
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
Jul 09, 2026 05:00 AM · gurufocus.com
Dexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern Time
Jul 09, 2026 04:30 AM · businesswire.com
Here's Why DexCom (DXCM) is a Strong Growth Stock
Jul 08, 2026 06:45 AM · zacks.com
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
Jul 06, 2026 11:36 AM · zacks.com
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Jul 03, 2026 08:27 AM · prnewswire.com
DexCom: The Growth Thesis Still Needs To Be Proven
Jul 01, 2026 10:10 PM · seekingalpha.com
Abbott vs. DexCom: Which CGM Stock Is the Better Option Right Now?
Jun 26, 2026 05:36 AM · zacks.com
DexCom to Roll Out Reimagined Stelo App With Global Expansion Plans
Jun 24, 2026 06:31 AM · zacks.com
Dexcom Further Advances Vision of Glucose Biosensing for All
Jun 23, 2026 05:00 AM · businesswire.com
3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Jun 20, 2026 04:45 AM · marketbeat.com